Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 3
1991 3
1992 1
1993 1
1994 1
1996 2
1997 1
1998 3
1999 1
2000 1
2002 1
2003 3
2008 2
2009 2
2014 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.
Kieback AG, Felix SB, Reffelmann T. Kieback AG, et al. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. Expert Opin Drug Metab Toxicol. 2009. PMID: 19761414 Review.
Quinaprilat is excreted mainly in urine. In long-term animal studies, quinaprilat was not teratogenic, mutagenic or carcinogenic. However, due to the risk of fetal and neonatal morbidity and death, it should not be administrated in pregnancy. Quinaprilat is c …
Quinaprilat is excreted mainly in urine. In long-term animal studies, quinaprilat was not teratogenic, mutagenic or carcinogen …
Quinapril: a new second-generation ACE inhibitor.
Cetnarowski-Cropp AB. Cetnarowski-Cropp AB. DICP. 1991 May;25(5):499-504. doi: 10.1177/106002809102500510. DICP. 1991. PMID: 2068835 Review.
The drug undergoes hepatic hydrolysis into its major active diacid metabolite, quinaprilat, and two minor inactive metabolites. On a weight basis quinaprilat is three times as potent an ACE inhibitor as quinapril. ...Quinaprilat has a strong binding capacity …
The drug undergoes hepatic hydrolysis into its major active diacid metabolite, quinaprilat, and two minor inactive metabolites. On a …
Electrophysiologic effects of quinaprilat in dogs during acute myocardial ischemia and following reperfusion.
Fujinaga H, Wakatsuki T, Nishikado A, Oki T, Ito S. Fujinaga H, et al. Coron Artery Dis. 1998;9(10):697-701. Coron Artery Dis. 1998. PMID: 9894622
BACKGROUND: There have been few studies concerning the electrophysiologic changes associated with the use of angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction. We examined the electrophysiologic effects of quinaprilat in dogs duri …
BACKGROUND: There have been few studies concerning the electrophysiologic changes associated with the use of angiotensin-converting enzyme i …
Protective effects of quinaprilat and trandolaprilat, active metabolites of quinapril and trandolapril, on hemolysis induced by lysophosphatidylcholine in human erythrocytes.
Hayase N, Satomi M, Hara A, Awaya T, Shimizu K, Matsubara K. Hayase N, et al. Biol Pharm Bull. 2003 May;26(5):712-6. doi: 10.1248/bpb.26.712. Biol Pharm Bull. 2003. PMID: 12736518 Free article.
We examined the effects of the angiotensin converting enzyme (ACE) inhibitors captopril, enalaprilat, quinapril, and trandolapril, and their active metabolites quinaprilat and trandolaprilat, on hemolysis induced by lysophosphatidylcholine (LPC) in human erythrocyte …
We examined the effects of the angiotensin converting enzyme (ACE) inhibitors captopril, enalaprilat, quinapril, and trandolapril, an …
Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure.
Wolter K, Fritschka E. Wolter K, et al. Eur J Clin Pharmacol. 1993;44 Suppl 1:S53-6. doi: 10.1007/BF01428395. Eur J Clin Pharmacol. 1993. PMID: 8387427
The pharmacokinetics and pharmacodynamics of the ACE inhibitor quinaprilat have been studied in six chronic haemodialysis (HD) patients and in six patients undergoing continuous ambulatory peritoneal dialysis (CAPD) after a single oral dose of 2.5 mg quinapril. Mean tmax a …
The pharmacokinetics and pharmacodynamics of the ACE inhibitor quinaprilat have been studied in six chronic haemodialysis (HD) patien …
Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
Davis JL, Kruger K, LaFevers DH, Barlow BM, Schirmer JM, Breuhaus BA. Davis JL, et al. Equine Vet J. 2014 Nov;46(6):729-33. doi: 10.1111/evj.12206. Epub 2014 Jan 7. Equine Vet J. 2014. PMID: 24175935 Clinical Trial.
Noncompartmental pharmacokinetic modelling and statistical analyses were performed. RESULTS: No adverse effects were observed during the study period. Intravenous and oral administration significantly inhibited ACE activity. ...Maximum concentration for quinapril …
Noncompartmental pharmacokinetic modelling and statistical analyses were performed. RESULTS: No adverse effects were observed …
Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis.
Swartz RD, Starmann B, Horvath AM, Olson SC, Posvar EL. Swartz RD, et al. J Clin Pharmacol. 1990 Dec;30(12):1136-41. doi: 10.1002/j.1552-4604.1990.tb01857.x. J Clin Pharmacol. 1990. PMID: 2273086 Free article.
Overall, quinapril was well tolerated by these CAPD patients, with mild and transient side effects, not unexpected in this clinical setting, which included pruritus, headache, nausea, and cough. ...The elimination half-life of quinaprilat was markedly prolonged when …
Overall, quinapril was well tolerated by these CAPD patients, with mild and transient side effects, not unexpected in this clinical s …
[Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure].
Mitrovic V, Mudra H, Bonzel T, Schmidt W, Schlepper M. Mitrovic V, et al. Z Kardiol. 1996 Nov;85(11):828-38. Z Kardiol. 1996. PMID: 9064945 Clinical Trial. German.
The hemodynamic and neurohumoral effects of single and multiple doses of intravenous quinaprilat were assessed and compared with placebo in a double-blind design. ...The study results obtained in patients with advanced heart failure support both the safety and favor …
The hemodynamic and neurohumoral effects of single and multiple doses of intravenous quinaprilat were assessed and compared wi …
Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomy.
Appenroth D, Beutinger R, Lupp A, Fleck C. Appenroth D, et al. Exp Toxicol Pathol. 2003 Jun;54(5-6):359-66. doi: 10.1078/0940-2993-00271. Exp Toxicol Pathol. 2003. PMID: 12877346
The renoprotective effect of losartan and quinaprilat was tested in two different animal models of renal failure [female Wistar rats, single administration of 0.5 mg uranyl nitrate (UN)/100 g body wt. or 5/6 nephrectomy (5/6NX)]. Losartan (1 mg/100 g body weight [wt.]) and …
The renoprotective effect of losartan and quinaprilat was tested in two different animal models of renal failure [female Wistar rats, …
Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries.
van Beusekom HM, Ferrero V, Ribichini F, van der Giessen WJ. van Beusekom HM, et al. Atherosclerosis. 2009 Jul;205(1):120-5. doi: 10.1016/j.atherosclerosis.2008.11.029. Epub 2008 Dec 6. Atherosclerosis. 2009. PMID: 19135197
The aim of this study was to evaluate the angiographic and histomorphologic effects of quinaprilat-eluting stents in normal porcine coronary arteries. ...CONCLUSION: Quinaprilat-eluting stents do not attenuate neointimal thickening following implantation in n …
The aim of this study was to evaluate the angiographic and histomorphologic effects of quinaprilat-eluting stents in normal po …
27 results